These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Failure to thrive in HIV-infected children: incidence, prevalence, and clinical correlates.
    Author: Myhre JA, Chadwick EG, Yogev R.
    Journal: Pediatr AIDS HIV Infect; 1996 Apr; 7(2):83-90. PubMed ID: 11361485.
    Abstract:
    "Failure to thrive" is a frequent component of the acquired immunodeficiency syndrome (AIDS) in childhood. This retrospective study was conducted to document the incidence, prevalence, and clinical correlates of "failure to thrive" in a cohort of 97 HIV-infected children seen at a large urban teaching hospital over an 8-year period. "Failure to thrive" was defined as percent of body weight for height age < or = 90%. The cumulative incidence of failure to thrive in our cohort was 37/97 (38%), with a current prevalence of 13/97 (14%). When 33 patients with severe symptomatic HIV infection [Centers for Disease Control (CDC) class C] were analyzed separately, the cumulative incidence rose to 22/33 (67%) and current prevalence to 9/33 (27%). CDC class C correlated with failure to thrive (p < 0.001), as did absolute CD4 cell count more than two standard deviations below the mean for age (p < 0.001). Neither the mode of acquisition of HIV infection nor the presence of HIV antigenemia correlated with failure to thrive. During follow-up, 34/37 patients with failure to thrive gained weight; in 17 this was associated with specific nutritional therapy. Treatment with zidovudine (AZT) was also associated with a significant weight gain (p < 0.01). The incidence and prevalence of failure to thrive in our cohort are lower than in previous reports. We conclude that enrollment of HIV-infected children in a comprehensive clinic providing nutritional evaluation, supplemental feeding, treatment of opportunistic infections, antiretroviral medications, and psychosocial support will likely continue to reduce the incidence and prevalence of "failure to thrive."
    [Abstract] [Full Text] [Related] [New Search]